Eleonora Farina1, Jenny Capuccini1, Gabriella Macchia2, Luciana Caravatta3, Nam P Nguyen4, Silvia Cammelli1, Giuseppe Zanirato Rambaldi5, Savino Cilla6, Tigeneh Wondemagegnhu7, A F M Kamal Uddin8, Mostafà Aziz Sumon9, Domenico Genovesi3, Milly Buwenge1, Francesco Cellini10, Vincenzo Valentini10, Francesco Deodato11, Alessio G Morganti1. 1. Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138, Bologna, Italy. 2. Radiotherapy Unit, Department of Oncology, "Giovanni Paolo II" Foundation, Catholic University of Sacred Heart, Largo Agostino Gemelli 1, 86100, Campobasso, Italy. Electronic address: radiotherapy.ef@gmail.com. 3. Department of Radiation Oncology, SS. Annunziata Hospital, G. D'Annunzio University of Chieti, V. dei Vestini, 66100, Chieti, Italy. 4. Department of Radiation Oncology, Howard University College of Medicine, 520 W St NW, Washington, DC, 20059, USA. 5. Radiology Unit, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, S. Orsola-Malpighi Hospital, V. Massarenti 9, 40138, Bologna, Italy. 6. Medical Physics Unit, "Giovanni Paolo II" Foundation, Catholic University of Sacred Heart, Largo Agostino Gemelli 1, 86100, Campobasso, Italy. 7. Department of Radiotherapy, Black Lion Hospital, Zambia St, Addis-Ababa, Ethiopia. 8. Department of Radiation Oncology, United Hospital Limited, Plot 15, Road 71, Gulshan, Dhaka 1212, Bangladesh. 9. Clinical Oncology, Kurmitola General Hospital, Tongi Diversion Rd, Dhaka 1206, Bangladesh. 10. Department of Radiotherapy, "A. Gemelli" Hospital, Catholic University, Largo Agostino Gemelli 8, 00168, Rome, Italy. 11. Radiotherapy Unit, Department of Oncology, "Giovanni Paolo II" Foundation, Catholic University of Sacred Heart, Largo Agostino Gemelli 1, 86100, Campobasso, Italy.
Abstract
OBJECTIVES: To evaluate the efficacy and safety of a conformal Short Course Accelerated Radiation therapy (SHARON) for symptomatic palliation of locally advanced or metastatic cancers in older patients. MATERIALS AND METHODS: This is a pooled analysis on patients aged ≥80 years selected between subjects enrolled in 3 phase I-II studies on a short course palliative treatment of advanced or metastatic cancer. The primary endpoint was to evaluate the symptoms response rate produced by accelerated radiotherapy delivered in 4 total fractions in twice a day. Total dose ranged between 14 Gy and 20 Gy while dose/fraction between 3.5 and 5 Gy. RESULTS: A total of 48 patients were included in this analysis. Twenty-six patients (54.2%) had advanced primary or metastatic head and neck tumors, 11 (22.9%) locally advanced or metastatic thoracic cancers, 11 (22.9%) complicated bone metastases. The majority of patients presented pain (60.4%). With a median follow-up time of 5.5 months, no G4 acute and late toxicities were recorded. The overall palliative response rate was 91.7% with a median duration of palliation of 4 months. CONCLUSION: Short course accelerated radiotherapy in locally advanced or metastatic cancers is effective in terms of symptom relief and well tolerated even in older patients.
OBJECTIVES: To evaluate the efficacy and safety of a conformal Short Course Accelerated Radiation therapy (SHARON) for symptomatic palliation of locally advanced or metastatic cancers in older patients. MATERIALS AND METHODS: This is a pooled analysis on patients aged ≥80 years selected between subjects enrolled in 3 phase I-II studies on a short course palliative treatment of advanced or metastatic cancer. The primary endpoint was to evaluate the symptoms response rate produced by accelerated radiotherapy delivered in 4 total fractions in twice a day. Total dose ranged between 14 Gy and 20 Gy while dose/fraction between 3.5 and 5 Gy. RESULTS: A total of 48 patients were included in this analysis. Twenty-six patients (54.2%) had advanced primary or metastatic head and neck tumors, 11 (22.9%) locally advanced or metastatic thoracic cancers, 11 (22.9%) complicated bone metastases. The majority of patients presented pain (60.4%). With a median follow-up time of 5.5 months, no G4 acute and late toxicities were recorded. The overall palliative response rate was 91.7% with a median duration of palliation of 4 months. CONCLUSION: Short course accelerated radiotherapy in locally advanced or metastatic cancers is effective in terms of symptom relief and well tolerated even in older patients.
Authors: Jenny Capuccini; Gabriella Macchia; Eleonora Farina; Milly Buwenge; Domenico Genovesi; Luciana Caravatta; Nam P Nguyen; Silvia Cammelli; Savino Cilla; Tigeneh Wondemagegnhu; A F M Kamal Uddin; Mostafà Aziz Sumon; Francesco Cellini; Vincenzo Valentini; Francesco Deodato; Alessio G Morganti Journal: Clin Exp Metastasis Date: 2018-08-18 Impact factor: 5.150
Authors: Eleonora Farina; Gabriella Macchia; Milly Buwenge; Giambattista Siepe; Alice Zamagni; Silvia Cammelli; Savino Cilla; Tigeneh Wondemagegnhu; Aynalem A Woldemariam; A F M Kamal Uddin; Mostafà Aziz Sumon; Francesco Cellini; Francesco Deodato; Alessio G Morganti Journal: Clin Exp Metastasis Date: 2018-10-08 Impact factor: 5.150
Authors: Alessio G Morganti; Gabriella Macchia; Francesco Cellini; Francesco Deodato; Alice Zamagni; Giambattista Siepe; Milly Buwenge Journal: Front Oncol Date: 2022-02-23 Impact factor: 6.244